HLX10 + HLX04 + carboplatin + pemetrexed

This is a four-drug combination therapy consisting of HLX10 (a recombinant humanized anti-programmed cell death protein 1 (PD-1) monoclonal antibody), HLX04 (a bevacizumab biosimilar targeting vascular endothelial growth factor A), carboplatin (a platinum-based chemotherapy), and pemetrexed (an antimetabolite chemotherapy). HLX10 is being developed for immunotherapy of solid tumors, acting as an immune checkpoint inhibitor. HLX04, developed as a bevacizumab biosimilar, inhibits angiogenesis via VEGFA blockade. In the described combination, these agents are used together for the first-line treatment of advanced non-squamous non-small cell lung cancer (nsNSCLC), with trials aiming to improve efficacy by combining immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy[1][3][5].